MINI FUTURE OPTIONSSCHEIN CALL - ELI LILLY & CO | Delayed Deutsche Boerse AG 14:04:20 27/06/2024 BST | ||
| 50.11 EUR | +0.44% |
|
| Current month | +20.57% | ||
| 1 month | +22.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 50.11 | +0.44% |
| 26/06/24 | 49.89 | +0.18% |
| 25/06/24 | 49.8 | +2.03% |
| 24/06/24 | 48.81 | +1.08% |
| 21/06/24 | 48.29 | +0.48% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 02:04 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | DZ BANK |
| WKN | DJ1B0Y |
| ISIN | DE000DJ1B0Y7 |
| Date issued | 26/04/2023 |
| Strike | 369.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.21 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 50.62 € |
|---|---|
| Lowest since issue | 3.16 € |
| Spread | 0.04 € |
| Spread % | 0.08% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
